Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project
- Evaluate the effects of losartan potassium on disease progression in patients with
idiopathic pulmonary fibrosis.
- Determine the safety of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral losartan potassium daily for 1 year in the absence of disease
progression or unacceptable toxicity.
Patients undergo pulmonary function tests with gas diffusion lung volumes, DLCO tests, and
6-minute walk tests at baseline and then at 3, 6, 9, and 12 months. Patients also complete
baseline/transition dyspnea index questionnaires at baseline and then at 1, 3, 6, 9, and 12
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Stable or improved forced vital capacity (FVC) response at 1 year
Marisa Couluris, DO
University of South Florida
United States: Data and Safety Monitoring Board
SCUSF 0108 Pilot
|University of Cincinnati||Cincinnati, Ohio 45267-0502|